Loading
OrigiMed's personalised blood test for leftover cancer, which deliberately tracks only mutations shared by every tumour cell.
OriMIRACLE S was developed by OrigiMed of Shanghai and described in Cancer Medicine in 2023 (Qi et al.) in 127 patients with gastrointestinal tumours: panels of 21 to 30 clonal variants, positivity defined by three detected sites, residual disease detected before surgery in 18 of 26 patients and after surgery in 24 of 82. A 2024 study of 59 patients with osteosarcoma at Sun Yat-sen University, with OrigiMed co-authors and the same variant selection, found that ctDNA after surgery predicted event-free survival and preceded imaging by an average of 92.6 days in five patients.
Whole-exome sequencing of tumour and matched normal DNA; the OriSelector algorithm picks clonal single-nucleotide variants for a patient-specific multiplex PCR panel, and a sample is called positive when three tracked sites are detected.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Residual disease blood tests extend to bone sarcoma. The methods state a variant allele frequency limit of 0.01 per cent.
A residual disease test built on clonal variants only, which detects the trunk of the tumour and by design not its branches.
Query for this drug: (TITLE:"OriMIRACLE S" OR ABSTRACT:"OriMIRACLE S" OR TITLE:"OriMIRACLE" OR ABSTRACT:"OriMIRACLE" OR TITLE:"Minimal Residual Circulating Nucleic Acid Longitudinal Detection in Solid Tumor" OR ABSTRACT:"Minimal Residual Circulating Nucleic Acid Longitudinal Detection in Solid Tumor") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OriMIRACLE S, not a curated reading list.
Shares Tumour-informed versus tumour-naive ctDNA assays, Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA) and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA) and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/